-

Agilent to Webcast Fourth-Quarter Fiscal Year 2020 Financial Results Presentation, Sets Date for Virtual Analyst and Investor Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release fourth-quarter fiscal year 2020 financial results after the stock market closes on Monday, Nov. 23. The company will host a live webcast of its investor conference call in listen-only mode on the same day.

The company will also host an Analyst and Investor meeting on Wednesday, Dec. 9. The meeting, which will be conducted in a virtual format, will include presentations by Agilent’s senior management team on the company’s long-range strategies for accelerating revenue growth and shareholder value creation. The meeting will include a live question and answer session following the presentations.

Details for both webcasts:

Agilent Fourth-Quarter Earnings Webcast
Monday, Nov. 23, 2020 at 1:30 p.m. Pacific time

Agilent 2020 Virtual Analyst and Investor Meeting
Wednesday, Dec. 9, 2020 at 7 a.m. Pacific time

Links to the events will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website. The webcasts will remain on the company site for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent will release fiscal fourth quarter financial results Mon., Nov. 23. and will also host a virtual analyst and investor event Wed., Dec. 9.
Release Versions
$Cashtags

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea...

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo...

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD...
Back to Newsroom